pyrrolidinol esters, which were designed by structural recombination of the marketed M3 antagonists. As a result, two novel potent M3 antagonists, (R/S)-3-[2-hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromides (1 a: Ki =0.16 nm, IC50 =0.38 nm, t1/2 =9.34 min; 1 b: Ki =0.32 nm, IC50 =1.01 nm, t1/2 =19.2 min) with proper plasma stability were identified, which (particularly 1 a)
市售的用于治疗慢性阻塞性肺疾病的长效M3拮抗剂具有不适当的血浆稳定性(不稳定或过度不稳定),这会导致大量全身暴露或患者依从性差。为了发现具有适当血浆稳定性的新型M3拮抗剂,我们合成并
生物学评估了一系列
吡咯烷醇酯的手性季
铵盐,这些盐是通过市售M3拮抗剂的结构
重组设计的。结果,两种新型有效的M3拮抗剂(R / S)-3- [2-羟基-2,2-二(
噻吩-2-基)乙酰氧基] -
1,1-二甲基吡咯烷
溴化物(1 a:Ki = 0.16 nm,IC50 = 0.38 nm,t1 / 2 = 9.34 min; 1 b:Ki = 0.32 nm,IC50 = 1.01 nm,t1 / 2 = 19.2 min),具有适当的血浆稳定性,作为临床候选药物,其(特别是1a)有望克服目前市场上出售的M3拮抗剂的不适当稳定性所引起的缺点。另外,结构-活性关系研究表明,
吡咯烷基C 3原子的R构型明显优于S构型。